Healthcare and life sciences in China is in the midst of hyper-growth. According to EY analysts, the Chinese pharma market had an annual growth of 8% between 2014 to 2017. More important will be the number is projected to increase to about 14% between 2018 and 2020.
China [email protected] Hamburg will focus on China’s market entry and our KOLs will give you insights into this massive and unique market. Our panel consists of:
- CEO of a consulting firm well-connected both in Germany and in China, who has partnered with Medical Valley and shared healthcare insights with the former Chinese Minister of Health, Vice Chairman of the Standing Committee of the National People’s Congress, as well as members of the German parliament from various parties.
- Managing partner of the renowned KPCB China.
- European Operation VP of a Chinese biopharma company with its Dutch office focusing on collaborations with global pharma/biotech partners and research institutes.
- Senior VP of Research of a Chinese pharma which has recently established a licensing agreement with a multinational pharma company with expertise in the emerging market.
See here for a complete list of plenary sessions.
NEWLY ADDED SPEAKERS
 |
 |
|
Weiping Yang CEO ApolloBio Corporation |
Brian Yang Director of Business Development and Finance Terns Pharmaceuticals |
 |
 |
|
Jinchen Yu Senior Vice President, Research BIO-THERA |
Xiaofei Zhang VP, European Operations Link Health Group |
More speakers will be announced soon, register now and meet them in Hamburg！
| Register Now |